MedTrace Logo

Biobehavioral Correlates of Acute Phobic Fear

NCT03813823 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-01-23

No results posted yet for this study

Summary

This study seeks to measure the time course of circulating proinflammatory markers (interleukin-1 beta \[IL-1β\], interleukin-6 \[IL-6\], tumor necrosis factor alpha \[TNF-α\], and C-reactive protein \[CRP\]) and salivary alpha amylase (sAA) following laboratory fear arousal. Further, this study seeks to implement neurocognitive, physiological, and self-report measures to explore the role of threat sensitivity as a predictor of this response. The broad research question seeks to better understand the relationship between neurocognitive fear and subsequent stress responding elicited by both the immune system (i.e., proinflammatory markers) and autonomic nervous system (i.e., sAA). In light of these aims, the primary outcomes of the current study are the proinflammatory markers (IL-1β, IL-6, TNF-α, CRP), while secondary outcomes consist of sAA, neurocognitive measures (i.e., dot-probe task), physiological correlates (i.e., heart rate, galvanic skin response), and self-report measures.

Conditions

  • Phobia

Interventions

BEHAVIORAL

Fear tasks

All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.

Sponsors & Collaborators

  • University of Colorado, Boulder

    lead OTHER

Principal Investigators

  • Alex Kirk, M.A. · University of Colorado, Boulder

  • Joanna Arch, Ph.D. · University of Colorado, Boulder

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2019-08-01
Completion
2019-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03813823 on ClinicalTrials.gov